GlassScriptPhysician profile
Brian Ann Kluge
NPI 1386202430
$1,897.31
in general payments reported to CMS, 2019-2025
13 companies · $474 in 2025
The $474 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $130 · 2023: $401 · 2024: $892 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,483 · Travel and Lodging: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,482.65 |
| Travel and Lodging | $284.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $518.71 | 2023-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Genzyme Corporation | $375.06 | 2022-2025 | |
| Medical Device Business Services, INC. | $372.56 | 2024 | |
| Pulmonx Corporation | $173.60 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Stryker Corporation | $135.49 | 2025 | Flowtriever |
| Actelion Pharmaceuticals US, INC. | $130.21 | 2023 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $65.15 | 2025 | Breztri, Tezspire |
| Bard Peripheral Vascular, INC. | $24.28 | 2024 | |
| Viatris Specialty LLC | $23.76 | 2025 | Yupelri |
| Amgen INC. | $21.45 | 2025 | Tezspire |
| Verona Pharma, INC. | $20.48 | 2025 | Ohtuvayre |
| Haemonetics Corporation | $19.41 | 2024 | Teg5000 Hemostasis Analyzer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Kluge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.